稳态浓度腹膜透析的超滤与钠清除:前瞻性多中心随机交叉研究
本研究在家庭环境中比较Carry Life UF系统稳态浓度腹膜透析与标准2.5%葡萄糖CAPD交换的疗效与安全性。19例成人CAPD患者完成4周交叉研究,Carry Life UF在5小时治疗中超滤量较对照平均增加381 ml(95%CI 285–477),并提高腹膜钠清除与葡萄糖超滤效率,家庭使用安全性良好。
要点
- Carry Life UF较2.5%葡萄糖交换显著提高5小时超滤量,平均增加381 ml。
- 腹膜钠清除平均每交换增加43 mmol,葡萄糖超滤效率平均增加6.4 ml/g。
- 家庭使用4周耐受性良好,两研究臂各发生1例腹膜炎严重不良事件。
核心结论
- 在家庭环境下使用Carry Life UF系统的稳态浓度腹膜透析4周,显示出较2.5%葡萄糖对照交换更高的超滤量、腹膜钠清除和葡萄糖超滤效率,且安全可耐受。
研究设计与样本
- 前瞻性、多中心、随机、交叉研究,纳入每日2–4次交换且至少1次2.5%葡萄糖交换的成人CAPD患者,每研究臂家庭阶段4周,共19例完成(平均年龄56岁,女性6例,糖尿病7例)。
主要发现
- Carry Life UF 5小时治疗超滤量优于对照,达到预设250 ml优效界值,平均增加381 ml(95%CI 285–477)。
- Carry Life UF总组(11与15 g/h合并分析)平均超滤量513(251)ml,对照为132(172)ml。
- 腹膜钠清除较对照平均每交换增加43 mmol(95%CI 32–54)。
- 葡萄糖超滤效率较对照平均增加6.4 ml/g(95%CI 3.7–9.1)。
- 家庭阶段发生2例严重不良事件(腹膜炎),每研究臂各1例。
关键数值与推荐
- 主要结局预设优效界值为250 ml,Carry Life UF平均超滤量增加381 ml(95%CI 285–477)。
- Carry Life UF方案为每周3天以1.5%葡萄糖溶液填充、葡萄糖剂量11或15 g/h,另4天行1.5%葡萄糖交换。
临床怎么用
- 对需要改善液体管理的CAPD患者,可考虑以Carry Life UF稳态浓度腹膜透析替代每日1次2.5%葡萄糖交换,以提高超滤与钠清除。
局限性
- 样本量小(19例完成),家庭观察期仅4周,硬终点与长期安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The study assessed the efficacy and safety of steady concentration peritoneal dialysis using the Carry Life UF system in the home setting over 4 weeks. Treatment with the Carry Life UF system resulted in higher ultrafiltration volume, sodium removal, and glucose ultrafiltration efficiency compared with a 2.5% dextrose control exchange. The use of Carry Life UF in the home setting was well tolerated and safe, with no unexpected adverse events. BACKGROUND: Steady concentration peritoneal dialysis (PD) is a novel therapy for improved fluid management. We compared the efficacy and safety of steady concentration PD using the Carry Life UF system with a standard 2.5% dextrose continuous ambulatory peritoneal dialysis (CAPD) exchange in the home setting. METHODS: This is a prospective, multicenter, randomized, crossover study of adult patients on CAPD using 2-4 exchanges per day, with at least one daily 2.5% dextrose exchange. The home phase lasted 4 weeks for each study arm. During the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced with a Carry Life UF treatment 3 days/wk (1.5% dextrose solution for PD fill, 11 or 15 g/h glucose dose) and a 1.5% dextrose exchange 4 days/wk. The primary outcome was difference in ultrafiltration (UF) volume with 5-hour Carry Life UF treatment versus 5-hour 2.5% dextrose exchange (control). Secondary outcomes included adverse events, peritoneal sodium removal, and glucose UF efficiency. RESULTS: A total of 19 participants (mean [SD] age 56 [15] years, six women, seven with diabetes) completed the study. Peritoneal solute transfer rate categories were fast four, average 12, and slow three. The UF volume primary outcome was met as Carry Life UF was superior to control in a prespecified superiority margin of 250 ml, mean increase 381 ml, 95% confidence interval (CI, 285 to 477). For the Carry Life UF total group (11 and 15 g/h cohorts analyzed together), mean (SD) UF volume was 513 (251) versus 132 (172) ml for the control. The secondary outcome peritoneal sodium removal was greater with Carry Life UF versus control (mean increase 43 mmol/exchange, 95% CI, 32 to 54). The secondary outcome glucose UF efficiency (UF volume in relation to glucose absorption) was enhanced with Carry Life UF versus control (mean increase 6.4 ml/g, 95% CI, 3.7 to 9.1). Two serious adverse events (peritonitis) occurred in the home phase, one episode in each study arm. CONCLUSIONS: This 4-week home study of steady concentration PD using the Carry Life UF system demonstrated efficacy and safety. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT05874804 .
引用
- Wilkie M, Heimbürger O, de Leon C, et al. Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis: A Prospective, Multicenter, Randomized, Crossover Study. J Am Soc Nephrol. 2026. PMID: 42240452. doi:10.1681/ASN.0000001152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。